Biopharmaceutical CMO & CRO Market by Source (Mammalian, Non-Mammalian), Service Type (Contract Manufacturing, Contract Research), Product, Scale of Operation, Therapeutic Applications - Global Forecast 2024-2030

Biopharmaceutical CMO & CRO Market by Source (Mammalian, Non-Mammalian), Service Type (Contract Manufacturing, Contract Research), Product, Scale of Operation, Therapeutic Applications - Global Forecast 2024-2030


The Biopharmaceutical CMO & CRO Market size was estimated at USD 81.32 billion in 2023 and expected to reach USD 95.65 billion in 2024, at a CAGR 18.10% to reach USD 260.65 billion by 2030.

Global Biopharmaceutical CMO & CRO Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biopharmaceutical CMO & CRO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biopharmaceutical CMO & CRO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceutical CMO & CRO Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., arexel International Corporation, Baxter International Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific Limited, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON Plc, KBI Biopharma, Inc., KEMWELL BIOPHARMA PRIVATE LIMITED, Laboratory Corporation of America Holdings, Lonza Group AG, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Patheon Inc., Rentschler Biopharma SE, and Sterling Pharma Solutions.

Market Segmentation & Coverage



This research report categorizes the Biopharmaceutical CMO & CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

Source
Mammalian
Non-Mammalian
Service Type
Contract Manufacturing
Contract Research
Product
Biologics
Biosimilars
Scale of Operation
Clinical
Commercial
Therapeutic Applications
Cardiovascular Diseases
Infectious Disease
Neurology
Oncology
Ophthalmology
Respiratory Disorder
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biopharmaceutical CMO & CRO Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biopharmaceutical CMO & CRO Market?
3. What are the technology trends and regulatory frameworks in the Biopharmaceutical CMO & CRO Market?
4. What is the market share of the leading vendors in the Biopharmaceutical CMO & CRO Market?
5. Which modes and strategic moves are suitable for entering the Biopharmaceutical CMO & CRO Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biopharmaceutical CMO & CRO Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
5.1.1.2. Potential demand for macromolecular therapeutics
5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
5.1.2. Restraints
5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
5.1.3. Opportunities
5.1.3.1. Penetration of advanced technology in the biotechnology field
5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
5.1.4. Challenges
5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Biopharmaceutical CMO & CRO Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Non-Mammalian
7. Biopharmaceutical CMO & CRO Market, by Service Type
7.1. Introduction
7.2. Contract Manufacturing
7.3. Contract Research
8. Biopharmaceutical CMO & CRO Market, by Product
8.1. Introduction
8.2. Biologics
8.3. Biosimilars
9. Biopharmaceutical CMO & CRO Market, by Scale of Operation
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Biopharmaceutical CMO & CRO Market, by Therapeutic Applications
10.1. Introduction
10.2. Cardiovascular Diseases
10.3. Infectious Disease
10.4. Neurology
10.5. Oncology
10.6. Ophthalmology
10.7. Respiratory Disorder
11. Americas Biopharmaceutical CMO & CRO Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Biopharmaceutical CMO & CRO Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie, Inc.
15.1.2. arexel International Corporation
15.1.3. Baxter International Inc.
15.1.4. Boehringer Ingelheim Biopharmaceuticals GmbH
15.1.5. Boehringer Ingelheim GmbH
15.1.6. Catalent, Inc.
15.1.7. Charles River Laboratories International, Inc.
15.1.8. Eurofins Scientific Limited
15.1.9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.1.10. ICON Plc
15.1.11. KBI Biopharma, Inc.
15.1.12. KEMWELL BIOPHARMA PRIVATE LIMITED
15.1.13. Laboratory Corporation of America Holdings
15.1.14. Lonza Group AG
15.1.15. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
15.1.16. Patheon Inc.
15.1.17. Rentschler Biopharma SE
15.1.18. Sterling Pharma Solutions
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. BIOPHARMACEUTICAL CMO & CRO MARKET RESEARCH PROCESS
FIGURE 2. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2023 VS 2030
FIGURE 3. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOPHARMACEUTICAL CMO & CRO MARKET DYNAMICS
FIGURE 7. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 8. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
FIGURE 10. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 12. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
FIGURE 14. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
FIGURE 16. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings